History of Peritoneal Dialysis

Boen, S. T.

doi:10.1007/978-94-009-1085-0_1

Cited by 13 publications

(8 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The decision to report this AAPD experience is based solely on the fact that new approaches to therapy need pure clinical reports if they are to be developed into sound and successful options. The PD technique would not have achieved the position it has today as an important RRT option if it were not for small, purely clinical, studies carried out during the last few decades (27-29). The information provided here may shed some light on, or contribute to the establishment of, AAPD for a well-defined group of CKD patients as a reliable option and also as palliative care.…”

Section: Discussionmentioning

confidence: 99%

A Brazilian Experience in Assisted Automated Peritoneal Dialysis: A Reliable and Effective Home Care Approach

Franco

Fernandes

Ribeiro³

et al. 2012

Perit Dial Int

View full text Add to dashboard Cite

Introduction Automated assisted peritoneal dialysis (AAPD) has been shown to be successful as renal replacement therapy for elderly and physically incapable end-stage renal disease (ESRD) patients. In early 2003, a pioneer AAPD program was initiated at GAMEN Renal Clinic in Rio de Janeiro, Brazil. Objective We evaluated the results of an AAPD program offered as an option to elderly ESRD patients with physical or cognitive debilities or as last resort to patients with vascular access failure or hemodynamic instability during hemodialysis. Methods A cohort of 30 consecutive patients started AAPD from January 2003 to March 2008 and was followed to July 2009. Demographics, clinical and laboratory parameters, causes of death, and patient and technique survival were analyzed. Results Median age of the patients was 72 years (range: 47 – 93 years), with 60% being older than 65. The Davies score was greater than 2 in 73% of patients, and the Karnofsky index was less than 70 in 40%. The overall peritonitis rate was 1 episode in 37 patient–months. The total duration of AAPD ranged from 3 to 72 months. Patient survival was 80% at 12 months, 60% at 24 months, and 23.3% at 48 months. The most common cause of death was cardiovascular problems (70%). Conclusions In this clinical observational study, AAPD fulfilled its expected role, offering an opportune, reliable, and effective homecare alternative for ESRD patients with no other renal replacement therapy options.

show abstract

Section: Discussionmentioning

confidence: 99%

A Brazilian Experience in Assisted Automated Peritoneal Dialysis: A Reliable and Effective Home Care Approach

Franco

Fernandes

Ribeiro³

et al. 2012

Perit Dial Int

View full text Add to dashboard Cite

show abstract

“…4 In 1969, Boen's dialysate consisted of an acetate-based solution of 35 mEq/L with 130-140 mEq/L of sodium and 1.5-5 g/dL of glucose. 5 By then it had become evident that a PD solution should contain a buffer, electrolytes, and an osmotic agent. Lactate and acetate have been traditionally used as buffers in PD solutions, as they both have similar effects on maintaining the acid-base balance.…”

mentioning

confidence: 99%

PD solutions: New and old

Díaz-Buxó

Sawin

Himmele

2011

Dialysis & Transplantation

View full text Add to dashboard Cite

Peritoneal dialysis (PD) solutions have evolved since Boen described the appropriate composition of a suitable fluid comprising an osmotic agent, electrolytes, and buffer substance in 1969. New solutions introducing alternative osmotic agents and bicarbonate as an alternative to lactate‐buffered solutions have been developed. These so‐called biocompatible solutions belong to a very heterogeneous group of PD fluids that share some features but are distinct in other aspects. All biocompatible solutions have a substantially reduced level of toxic glucose degradation products (GDPs). However, the new solutions differ in their absolute GDP content, osmotic agent, buffer substance, and pH. The differences from the conventional solutions and the characteristics of the distinct new solutions are presented in this review together with a discussion of their potential clinical benefits and implications. Dial. Transplant. © 2011 Wiley Periodicals, Inc.

show abstract

“…The first commercial solutions for peritoneal dialysis (PD) became available in 1959 (1). Since that time, PD solutions have evolved so as to approximate a normal internal chemical milieu for individuals with end-stage renal disease (ESRD) and have prolonged their lives.…”

mentioning

confidence: 99%

Hyponatremia and Hypokalemia in Patients on Peritoneal Dialysis

Zanger

2010

Seminars in Dialysis

View full text Add to dashboard Cite

Hypokalemia occurs in up to 60% of patients on peritoneal dialysis (PD) for end-stage renal disease. It can be associated with poor clinical outcomes, including malnutrition and death. New evidence points to a link between hypokalemia and the risk of peritonitis. The serum Na(+) concentration is determined by the ratio of exchangeable Na(+) and K(+) to total body water. Hyponatremia may be caused by excessive thirst, a particular problem in patients on PD. Consistent with the relationship among the serum sodium concentration, total body cation content, and total body water, hyponatremia may also be caused by total body potassium depletion. Ultra-low sodium dialysis fluid may prove to have an important role in management of fluid overload and hypertension in patients on PD. Surprisingly, it is not associated with significant hyponatremia, for reasons that remain to be elucidated.

show abstract

History of Peritoneal Dialysis

Cited by 13 publications

References 60 publications

A Brazilian Experience in Assisted Automated Peritoneal Dialysis: A Reliable and Effective Home Care Approach

A Brazilian Experience in Assisted Automated Peritoneal Dialysis: A Reliable and Effective Home Care Approach

PD solutions: New and old

Hyponatremia and Hypokalemia in Patients on Peritoneal Dialysis

Contact Info

Product

Resources

About